What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 1).

December 8, 2025BloodOpen Access

Trial in progress: Phase I trial to evaluate safety of oral azacytidine in combination with pomalidomide as maintenance therapy in AML

View Full Paper

Ask AI

Bookmark

Combination of pomalidomide and oral azacitidine aims to enhance immune-mediated disease control in acute myeloid leukemia.
Establishment of maximum tolerated dose and safety profile is critical for further development of maintenance therapy.
Single-center phase I trial incorporates dose escalation and predefined de-escalation cohorts to ensure patient safety.
Emerging predictive biomarkers through gene expression analysis and immunophenotyping could guide future AML therapies.

Authors

TEThomas EipeHomi Bhabha National Institute HJHasmukh JainHomi Bhabha National Institute LNLingaraj NayakHomi Bhabha National Institute

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Phase I trial assesses maximum tolerated dose and safety profile of pomalidomide and azacitidine in AML, indicating potential for improved relapse outcomes.

Cite This Study

Eipe et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1de https://doi.org/10.1182/blood-2025-8251

View Full Paper

Ask AI

Bookmark

Implication

Phase I trial assesses maximum tolerated dose and safety profile of pomalidomide and azacitidine in AML, indicating potential for improved relapse outcomes.

Trial in progress: Phase I trial to evaluate safety of oral azacytidine in combination with pomalidomide as maintenance therapy in AML

Key Points

Discussion

Implication

Cite This Study

Trial in progress: Phase I trial to evaluate safety of oral azacytidine in combination with pomalidomide as maintenance therapy in AML

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider